Key insights
- Becton Dickinson EVP Michael Garrison sold $166,628 in stock under a pre-arranged plan. While this is insider selling, the company recently beat Q2 earnings and revenue expectations, and introduced a new laser system. InvestingPro suggests the stock is undervalued. The sale occurred under a 10b5-1 plan, and the executive still holds a significant number of shares. The transaction's impact on the broader US equity market is minimal.
Michael David Garrison, Executive Vice President and President of Medical Essentials and BioPharm at Becton Dickinson & Co (NYSE:BDX), sold shares of the company’s common stock totaling $166,628 on June 10, 2026.
The transaction involved the disposal of 1,100 shares at a price of $151.48 per share. This sale was executed under a Rule 10b5-1 trading plan, which Mr. Garrison adopted on February 18, 2026.
Following this transaction, Mr. Garrison directly holds 14,272 shares of Becton Dickinson common stock. Notably, the stock currently trades at $147.35, below the executive’s sale price, and analysis from InvestingPro suggests the company is undervalued relative to its Fair Value, placing it among compelling opportunities on the platform’s most undervalued stocks list. The healthcare equipment giant, which has raised its dividend for 55 consecutive years, is covered in depth through a comprehensive Pro Research Report available to subscribers. These direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by Mr. Garrison.
In other recent news, Becton Dickinson (BD) reported its Q2 2026 earnings, exceeding analyst expectations with an adjusted earnings per share (EPS) of $2.90, surpassing the forecasted $2.78. The company’s revenue for the quarter was $4.7 billion, slightly above the anticipated $4.67 billion. Additionally, BD has introduced the Elyra Thulium Fiber Laser System, designed for urologic stone management and soft tissue procedures. This new system comes in two configurations, Elyra and Elyra Plus, to meet varying operational needs. In financial developments, BD’s subsidiary, Becton Dickinson Euro Finance S.à r.l., completed an underwritten public offering of €600 million in notes due 2033, guaranteed by BD. Furthermore, BD has appointed Peter Menziuso as the executive vice president and president of its Interventional unit, effective June 1. Menziuso previously held a leadership role at Johnson & Johnson Vision. These recent developments highlight BD’s ongoing strategic and financial activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Before you click "buy," know exactly where to set your stop-loss. Our Vision AI literally "sees" your BDX chart and delivers a complete risk management plan—entry, stop-loss, and profit target—in under 60 seconds.Protect your downside. Validate every trade. Invest smarter.